What is the Market's View on Cellectar Biosciences Inc (CLRB) Stock's Price and Volume Trends Wednesday?

Overall market sentiment has been high on Cellectar Biosciences Inc (CLRB) stock lately. CLRB receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Cellectar Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CLRB!

See Full CLRB Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CLRB Stock Today?

Cellectar Biosciences Inc (CLRB) stock is trading at $0.61 as of 3:11 PM on Wednesday, Jul 20, a gain of $0.12, or 24.49% from the previous closing price of $0.49. The stock has traded between $0.49 and $0.66 so far today. Volume today is high. So far 802,420 shares have traded compared to average volume of 97,357 shares. To screen for more stocks like Cellectar Biosciences Inc click here.

More About Cellectar Biosciences Inc

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. Click Here to get the full Stock Report for Cellectar Biosciences Inc stock.